150 related articles for article (PubMed ID: 21029363)
21. Anti-tumor necrosis factor antibody impairs the therapeutic effect of ceftriaxone in murine pneumococcal pneumonia.
Rijneveld AW; Florquin S; Hartung T; Speelman P; van der Poll T
J Infect Dis; 2003 Jul; 188(2):282-5. PubMed ID: 12854084
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of Phosphodiesterase-4 during Pneumococcal Pneumonia Reduces Inflammation and Lung Injury in Mice.
Tavares LP; Garcia CC; Vago JP; Queiroz-Junior CM; Galvão I; David BA; Rachid MA; Silva PM; Russo RC; Teixeira MM; Sousa LP
Am J Respir Cell Mol Biol; 2016 Jul; 55(1):24-34. PubMed ID: 26677751
[TBL] [Abstract][Full Text] [Related]
23. Recombinant thrombomodulin attenuates hyper-inflammation and glycocalyx damage in a murine model of Streptococcus pneumoniae-induced sepsis.
Watanabe E; Akamatsu T; Ohmori M; Kato M; Takeuchi N; Ishiwada N; Nishimura R; Hishiki H; Fujimura L; Ito C; Hatano M
Cytokine; 2022 Jan; 149():155723. PubMed ID: 34662822
[TBL] [Abstract][Full Text] [Related]
24. Treatment of severe pneumonia by hinokitiol in a murine antimicrobial-resistant pneumococcal pneumonia model.
Isono T; Domon H; Nagai K; Maekawa T; Tamura H; Hiyoshi T; Yanagihara K; Kunitomo E; Takenaka S; Noiri Y; Terao Y
PLoS One; 2020; 15(10):e0240329. PubMed ID: 33057343
[TBL] [Abstract][Full Text] [Related]
25. Coagulation factor XI improves host defence during murine pneumonia-derived sepsis independent of factor XII activation.
Stroo I; Zeerleder S; Ding C; Luken BM; Roelofs JJTH; de Boer OJ; Meijers JCM; Castellino FJ; van 't Veer C; van der Poll T
Thromb Haemost; 2017 Jul; 117(8):1601-1614. PubMed ID: 28492700
[TBL] [Abstract][Full Text] [Related]
26. Antibody Treatment against Angiopoietin-Like 4 Reduces Pulmonary Edema and Injury in Secondary Pneumococcal Pneumonia.
Li L; Foo BJW; Kwok KW; Sakamoto N; Mukae H; Izumikawa K; Mandard S; Quenot JP; Lagrost L; Teh WK; Singh Kohli G; Zhu P; Choi H; Buist ML; Seet JE; Yang L; He F; Kwong Chow VT; Tan NS
mBio; 2019 Jun; 10(3):. PubMed ID: 31164474
[TBL] [Abstract][Full Text] [Related]
27. Delay in antibiotic therapy results in fatal disease outcome in murine pneumococcal pneumonia.
Berger S; Goekeri C; Gupta SK; Vera J; Dietert K; Behrendt U; Lienau J; Wienhold SM; Gruber AD; Suttorp N; Witzenrath M; Nouailles G
Crit Care; 2018 Nov; 22(1):287. PubMed ID: 30382866
[TBL] [Abstract][Full Text] [Related]
28. Thrombocytopenia impairs host defense during murine Streptococcus pneumoniae pneumonia.
van den Boogaard FE; Schouten M; de Stoppelaar SF; Roelofs JJ; Brands X; Schultz MJ; van't Veer C; van der Poll T
Crit Care Med; 2015 Mar; 43(3):e75-83. PubMed ID: 25627210
[TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia.
Ng W; Lutsar I; Wubbel L; Ghaffar F; Jafri H; McCracken GH; Friedland IR
J Antimicrob Chemother; 1999 Jun; 43(6):811-6. PubMed ID: 10404320
[TBL] [Abstract][Full Text] [Related]
30. The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia.
van Zoelen MA; Schouten M; de Vos AF; Florquin S; Meijers JC; Nawroth PP; Bierhaus A; van der Poll T
J Immunol; 2009 Apr; 182(7):4349-56. PubMed ID: 19299735
[TBL] [Abstract][Full Text] [Related]
31. Impact of the factor V Leiden mutation on the outcome of pneumococcal pneumonia: a controlled laboratory study.
Schouten M; van't Veer C; Roelofs JJ; Levi M; van der Poll T
Crit Care; 2010; 14(4):R145. PubMed ID: 20682036
[TBL] [Abstract][Full Text] [Related]
32. In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model.
Moine P; Vallée E; Azoulay-Dupuis E; Bourget P; Bédos JP; Bauchet J; Pocidalo JJ
Antimicrob Agents Chemother; 1994 Sep; 38(9):1953-8. PubMed ID: 7811003
[TBL] [Abstract][Full Text] [Related]
33. Mast cells impair host defense during murine Streptococcus pneumoniae pneumonia.
van den Boogaard FE; Brands X; Roelofs JJ; de Beer R; de Boer OJ; van 't Veer C; van der Poll T
J Infect Dis; 2014 Nov; 210(9):1376-84. PubMed ID: 24823624
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-10 impairs host defense in murine pneumococcal pneumonia.
van der Poll T; Marchant A; Keogh CV; Goldman M; Lowry SF
J Infect Dis; 1996 Nov; 174(5):994-1000. PubMed ID: 8896500
[TBL] [Abstract][Full Text] [Related]
35. Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia.
de Jonge E; Dekkers PE; Creasey AA; Hack CE; Paulson SK; Karim A; Kesecioglu J; Levi M; van Deventer SJ; van der Poll T
J Infect Dis; 2001 Jun; 183(12):1815-8. PubMed ID: 11372037
[TBL] [Abstract][Full Text] [Related]
36. Antibacterial activity and PK/PD of ceftriaxone against penicillin-resistant Streptococcus pneumoniae and beta-lactamase-negative ampicillin-resistant Haemophilus influenzae isolates from patients with community-acquired pneumonia.
Ohno A; Ishii Y; Kobayashi I; Yamaguchi K
J Infect Chemother; 2007 Oct; 13(5):296-301. PubMed ID: 17982717
[TBL] [Abstract][Full Text] [Related]
37. Extremely low doses of tissue factor pathway inhibitor decrease mortality in a rabbit model of septic shock.
Matyal R; Vin Y; Delude RL; Lee C; Creasey AA; Fink MP
Intensive Care Med; 2001 Aug; 27(8):1274-80. PubMed ID: 11511939
[TBL] [Abstract][Full Text] [Related]
38. In vivo activity and pharmacokinetics of ziracin (SCH27899), a new long-acting everninomicin antibiotic, in a murine model of penicillin-susceptible or penicillin-resistant pneumococcal pneumonia.
Wang E; Simard M; Bergeron Y; Beauchamp D; Bergeron MG
Antimicrob Agents Chemother; 2000 Apr; 44(4):1010-8. PubMed ID: 10722505
[TBL] [Abstract][Full Text] [Related]
39. Protease-Activated Receptor 2 Facilitates Bacterial Dissemination in Pneumococcal Pneumonia.
van den Boogaard FE; Brands X; Duitman J; de Stoppelaar SF; Borensztajn KS; Roelofs JJTH; Hollenberg MD; Spek CA; Schultz MJ; van 't Veer C; van der Poll T
J Infect Dis; 2018 Apr; 217(9):1462-1471. PubMed ID: 29415278
[TBL] [Abstract][Full Text] [Related]
40. In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia.
Azoulay-Dupuis E; Vallee E; Veber B; Bedos JP; Bauchet J; Pocidalo JJ
Antimicrob Agents Chemother; 1992 Dec; 36(12):2698-703. PubMed ID: 1336343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
